258 related articles for article (PubMed ID: 15079003)
1. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy.
Hilz MJ; Brys M; Marthol H; Stemper B; Dütsch M
Neurology; 2004 Apr; 62(7):1066-72. PubMed ID: 15079003
[TBL] [Abstract][Full Text] [Related]
2. Small fiber dysfunction predominates in Fabry neuropathy.
Dütsch M; Marthol H; Stemper B; Brys M; Haendl T; Hilz MJ
J Clin Neurophysiol; 2002 Dec; 19(6):575-86. PubMed ID: 12488789
[TBL] [Abstract][Full Text] [Related]
3. Neurological complications in Fabry disease.
Dütsch M; Hilz MJ
Rev Med Interne; 2010 Dec; 31 Suppl 2():S243-50. PubMed ID: 21211673
[TBL] [Abstract][Full Text] [Related]
4. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.
Schiffmann R; Floeter MK; Dambrosia JM; Gupta S; Moore DF; Sharabi Y; Khurana RK; Brady RO
Muscle Nerve; 2003 Dec; 28(6):703-10. PubMed ID: 14639584
[TBL] [Abstract][Full Text] [Related]
5. Small fibers in Fabry disease: baseline and follow-up data under enzyme replacement therapy.
Üçeyler N; He L; Schönfeld D; Kahn AK; Reiners K; Hilz MJ; Breunig F; Sommer C
J Peripher Nerv Syst; 2011 Dec; 16(4):304-14. PubMed ID: 22176145
[TBL] [Abstract][Full Text] [Related]
6. Neuropathy and Fabry disease: pathogenesis and enzyme replacement therapy.
Schiffmann R
Acta Neurol Belg; 2006 Jun; 106(2):61-5. PubMed ID: 16898255
[TBL] [Abstract][Full Text] [Related]
7. Fabry disease.
Toyooka K
Handb Clin Neurol; 2013; 115():629-42. PubMed ID: 23931807
[TBL] [Abstract][Full Text] [Related]
8. Kidney function and 24-hour proteinuria in patients with Fabry disease during 36 months of agalsidase alfa enzyme replacement therapy: a Brazilian experience.
Thofehrn S; Netto C; Cecchin C; Burin M; Matte U; Brustolin S; Nunes AC; Coelho J; Tsao M; Jardim L; Giugliani R; Barros EJ
Ren Fail; 2009; 31(9):773-8. PubMed ID: 19925283
[TBL] [Abstract][Full Text] [Related]
9. [Fabry disease in Spain: first analysis of the response to enzyme replacement therapy].
Rivera Gallego A; López Rodríguez M; Barbado Hernández FJ; Barba Romero MA; García de Lorenzo Y Mateos A; Pintos Morelle G;
Med Clin (Barc); 2006 Oct; 127(13):481-4. PubMed ID: 17043001
[TBL] [Abstract][Full Text] [Related]
10. Agalsidase therapy in patients with Fabry disease on renal replacement therapy: a nationwide study in Italy.
Mignani R; Feriozzi S; Pisani A; Cioni A; Comotti C; Cossu M; Foschi A; Giudicissi A; Gotti E; Lozupone VA; Marchini F; Martinelli F; Bianco F; Panichi V; Procaccini DA; Ragazzoni E; Serra A; Soliani F; Spinelli L; Torti G; Veroux M; Cianciaruso B; Cagnoli L
Nephrol Dial Transplant; 2008 May; 23(5):1628-35. PubMed ID: 18057066
[TBL] [Abstract][Full Text] [Related]
11. Enzyme replacement therapy and intraepidermal innervation density in Fabry disease.
Schiffmann R; Hauer P; Freeman B; Ries M; Scott LJ; Polydefkis M; Brady RO; McArthur JC; Wagner K
Muscle Nerve; 2006 Jul; 34(1):53-6. PubMed ID: 16583374
[TBL] [Abstract][Full Text] [Related]
12. Nature and prevalence of pain in Fabry disease and its response to enzyme replacement therapy--a retrospective analysis from the Fabry Outcome Survey.
Hoffmann B; Beck M; Sunder-Plassmann G; Borsini W; Ricci R; Mehta A;
Clin J Pain; 2007; 23(6):535-42. PubMed ID: 17575495
[TBL] [Abstract][Full Text] [Related]
13. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).
Hoffmann B; Garcia de Lorenzo A; Mehta A; Beck M; Widmer U; Ricci R;
J Med Genet; 2005 Mar; 42(3):247-52. PubMed ID: 15744039
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of enzyme-replacement-therapy with agalsidase alfa in 36 treatment-naïve Fabry disease patients.
Tsuboi K; Yamamoto H
BMC Pharmacol Toxicol; 2017 Jun; 18(1):43. PubMed ID: 28592315
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.
Furujo M; Kubo T; Kobayashi M; Ohashi T
Mol Genet Metab; 2013 Nov; 110(3):405-10. PubMed ID: 23906479
[TBL] [Abstract][Full Text] [Related]
16. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
[TBL] [Abstract][Full Text] [Related]
17. Physiological characterization of neuropathy in Fabry's disease.
Luciano CA; Russell JW; Banerjee TK; Quirk JM; Scott LJ; Dambrosia JM; Barton NW; Schiffmann R
Muscle Nerve; 2002 Nov; 26(5):622-9. PubMed ID: 12402283
[TBL] [Abstract][Full Text] [Related]
18. Metronomic breathing shows altered parasympathetic baroreflex function in untreated Fabry patients and baroreflex improvement after enzyme replacement therapy.
Hilz MJ; Koehn J; Kolodny EH; Brys M; Moeller S; Stemper B
J Hypertens; 2011 Dec; 29(12):2387-94. PubMed ID: 21970939
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of nociceptive Aδ- and C-fiber dysfunction with lidocaine using intraepidermal electrical stimulation.
Kodaira M; Inui K; Kakigi R
Clin Neurophysiol; 2014 Sep; 125(9):1870-7. PubMed ID: 24566074
[TBL] [Abstract][Full Text] [Related]
20. Clinical observations on enzyme replacement therapy in patients with Fabry disease and the switch from agalsidase beta to agalsidase alfa.
Lin HY; Huang YH; Liao HC; Liu HC; Hsu TR; Shen CI; Li ST; Li CF; Lee LH; Lee PC; Huang CK; Chiang CC; Lin SP; Niu DM
J Chin Med Assoc; 2014 Apr; 77(4):190-7. PubMed ID: 24388678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
